The strength of our systematic review and NMA lies in the possibility of capturing and analyzing all the available evidence, including the most recent RCTs (with low risk of bias) on the different treatment schemes in patients with advanced or locoregionally advanced HER2+ BC progressing to trastuzumab and taxanes as well as their reproducibility. The gene discussed is ERBB2; the disease is breast cancer.